Biologic Therapy in Chronic Obstructive Pulmonary Disease
| Autor: | Julia W. Tripple, William J. Calhoun, Jennifer L. McCracken |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Exacerbation Neutrophils Immunology Pulmonary disease Inflammation Pulmonary Disease Chronic Obstructive 03 medical and health sciences 0302 clinical medicine medicine Humans Immunology and Allergy Molecular Targeted Therapy 030212 general & internal medicine Interleukin 5 Biological Products COPD business.industry Anti-Inflammatory Agents Non-Steroidal Antibodies Monoclonal Environmental exposure medicine.disease respiratory tract diseases Biological Therapy Eosinophils Clinical trial Treatment Outcome 030228 respiratory system Physical therapy Tumor necrosis factor alpha medicine.symptom business |
| Zdroj: | Immunology and Allergy Clinics of North America. 37:345-355 |
| ISSN: | 0889-8561 |
| DOI: | 10.1016/j.iac.2017.01.009 |
| Popis: | Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|